| 产品描述: | DT2216 是一种基于PROTAC技术的 BCL-XL 的强效选择性降解剂。DT2216 抑制各种BCL-XL依赖性白血病和癌细胞,但对血小板的毒性较小 |
| 靶点: |
BCL-XL |
| 体外研究: |
DT2216 is a BCL-XL proteolysis targeting chimera (PROTAC) that targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 is more potent against various BCL-XL-dependent leukemia and cancer cells but significantly less toxic to platelets than ABT263 in vitro because VHL is poorly expressed in platelets. |
| 体内研究: |
In vivo, DT2216 effectively inhibits the growth of several xenograft tumors as a single agent or in combination with other chemotherapeutic agents, without causing significant thrombocytopenia |
| 细胞实验: |
Cell lines: MOLT-4, RS4;11, NCI-H146, MDA-MB-231, PC-3, HepG2, SW620, 786-O, WI-38, HEK 293T cells Concentrations: 0.1 μM, 0.3 μM Incubation Time: 24 h Method: MOLT-4 cells are seeded in 60 mm dishes (2.5 × 106 cells in 5 mL complete cell culture medium/dish), and then treated with indicated concentrations of DT2216 or ABT263 for 24 h. Cells are lysed in 1X cell lysis buffer by subjecting them to a freeze-thaw cycle in ice-ethanol bath or by 30 min incubation on ice. |
| 动物实验: |
Animal Models: female 5–6 week-old CB-17 SCID, CB-17 SCID-beige, NOD-SCID mice Dosages: 7.5 mg/kg, 15 mg/kg, 25 mg/kg Administration: IP |
| 参考文献: |
1. Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0.648 ml |
3.242 ml |
6.484 ml |
| 5 mM |
0.13 ml |
0.648 ml |
1.297 ml |
| 10 mM |
0.065 ml |
0.324 ml |
0.648 ml |
| 50 mM |
0.013 ml |
0.065 ml |
0.13 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |